WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 11, 1472-1486. Review Article ISSN 2277–7105

VASCULITIS; CLASSIFICATION, PATHOPHYSIOLOGY, CLINICAL FEATURES AND MANAGEMANT- A REVIEW

S. Sivadharshini*[1], S. Senthilkumar[2], Dr. K. Rithika[2], A. Manisha[1], S. Jayaseelan[2]

[1]Students of SS Institute of Pharmacy, Sankaris.

[2]Assistant Professor, SS Institute of Pharmacy, Sankari.

Article Received on 05 May 2026,
Article Revised on 25 May 2026,
Article Published on 01 June 2026

https://doi.org//10.5281/zenodo.20457930

***Corresponding Author**
S. Sivadharshini
Students of SS Institute of Pharmacy, Sankaris.

How to cite this Article: S. Sivadharshini*[1], S. Senthilkumar[2], Dr. K. Rithika[2], A. Manisha[1], S. Jayaseelan[2] (2026). Vasculitis; Classification, Pathophysiology, Clinical Features And Managemant- A Review. World Journal of Pharmaceutical Research, 15(11), 1472–1486.

ABSTRACT

Vasculitis is a group of disorders that involve inflammation of blood vessels. This inflammation can cause damage to the blood vessels, reduce blood flow, lead to tissue ischemia, and potentially harm organs. The condition can affect blood vessels of various sizes and may occur as a primary issue or be secondary to infections, autoimmune diseases, drugs, or cancers. Vasculitis is generally classified into three types based on the size of the affected vessels: large, medium, and small vessel vasculitis, each with its own distinct features. The pathophysiology of vasculitis mainly involves mechanisms driven by the immune system. This includes immune complex buildup, such as anti-neutrophil cytoplasmic antibodies (ANCA), and the activation of inflammatory cells that lead to damage of the blood vessel lining. The signs and symptoms of vasculitis can vary greatly based on which organs are affected. Common symptoms include skin rashes, joint pain, kidney problems, respiratory issues, and neurological deficits. To diagnose vasculitis early, doctors evaluate clinical symptoms and support this with lab tests, imaging, and tissue analysis. Treating vasculitis mainly aims to control inflammation and prevent organ damage. This is typically done through corticosteroids, immunosuppressive drugs, and targeted biological treatments. This review focuses on the classification, mechanisms, clinical features, and current treatments for vasculitis, highlighting the need for early detection and proper care to improve patient outcomes.

KEYWORDS: Vasculitis is a group of disorders that involve inflammation of blood vessels.

INTRODUCTION

Vasculitis refers to a range of inflammatory disorders marked by inflammation and damage to blood vessel walls. This can lead to structural changes, narrowing of the lumen, blood clots, or aneurysm formation. The inflammation in blood vessels reduces blood flow to tissues and organs, leading to ischemia and varying degrees of organ dysfunction. Vasculitis can affect vessels of any size, from large arteries to small capillaries, and can involve either arteries, veins, or both. The disease varies greatly, from mild skin issues that resolve on their own to severe, life-threatening organ failure.

The causes of vasculitis are complicated and involve multiple factors. It can happen as a primary condition without a know cause or as a result of underlying issues such as autoimmune diseases, chronic infection, cancers, or side effects of drugs. Often, the specific cause is still unclear. Immune response mechanisms are key in the development of vasculitis. These include the buildup of immune complexes in blood vessel walls, activation of the complement system, accumulation of inflammatory cells, and the creation of autoantibodies (ANCA). These action lead to injury to the blood vessel lining, increased permeability, and resulting tissue damage.

Clinically, vasculitis shows a wide range of general symptoms like fever, weight loss, fatigue, and discomfort, along with specific signs depending on which vessels are affected. Skin issues are common and may appear as raised purple spots, sores, or lumps. Kidney involvement can cause blood and protein in urine, while lung vasculitis might lead to coughing up blood and breathing difficulties. Other system, including neurological, gastrointestinal, and musculoskeletal, can also be involved, making diagnosis more challenging. This variability often results in delayed diagnoses and poor management.

Diagnosing vasculitis accurately requires careful clinical evaluation, lab tests, imaging studies, and confirmation through biopsy. Classifying vasculitis based on the size of the blood vessels and the underlying processes is critical for making treatment decision. In recent decades, we have made important strides in understanding how vasculitis develops, which has led to targeted treatment strategies.

The main goals of managing vasculitis are to reduce inflammation, achieve remission, prevent relapses, and limit side effects from treatment. Corticosteroids are still the primary treatment, while immunosuppressive drugs and newer biological therapies have improved

long-term results. However, vasculitis still carries significant risks for illness and death if not diagnosed and treated quickly.

This review article offers a detailed overview of vasculitis, focusing on its classification, causes, clinical features, and current management methods, Understanding these aspects is vital for early diagnosis, appropriate treatment, and better outcomes for patients with vasculitis.

CLASSIFICATION OF VASCULITIS

Vasculitis is classified based on the size of the mostly affected blood vessels, as proposed by the chapel hill consensus conference. This classification aids in understanding the disease mechanism, clinical presentation, and management strategies.

1.Large Vessel Vasculitis

Large vessel vasculitis primarily affects major arteries such as the aorta and its main branches. Examples

- Giant Cell Arteritis (Temporal Arteritis): Commonly affects elderly individuals and involves the temporal arteries. It leads to headache, visual disturbances, and jaw claudication.
- Takayasu Arteritis: Typically affects young women and involves the aorta and its branches. It presents with limb claudication and reduced pulses.

2. Medium Vessels Vasculitis

Medium vessels vasculitis involves medium-sized arteries that supply vital organs.

Examples

- Polyarteritis Nodosa (PAN): This is characterized by inflammation that destroys medium-sized arteries, often linked with kidney, gastrointestinal, and neurological problems.
- Kawasaki Disease: Commonly seen in children, it primarily affects the coronary arteries and can lead to aneurysm formation.

3. Small Vessel vasculitis

Small vessel vasculitis affects arterioles, capillaries, and venules and is often tied to immune-related mechanisms.

Examples

❖ ANCA- Associated Vasculitis:

- Granulomatosis with Polyangiitis
- Microscopic Polyangiitis
- Eosinophilic Granulomatosis with polyangiitis

❖ Immune Complex-Mediated Vasculitis:

- Henoch-Schonlein Purpura
- Cryoglobulinemic Vasculitis
- Cutaneous Leukocytoclastic Vasculitis

4. Variable Vessel Vasculitis

This category includes vasculitis that affects vessels of different sizes.

Examples

❖ Behcet's Disease

❖ Cogan's Syndrome

5. Single- Organ Vasculitis

Vasculitis is limited to a single organ without affecting the whole body.

Examples

❖ Cutaneous small vessel vasculitis

❖ Isolated central nervous system vasculitis

6. Secondary Vasculitis

This type of vasculitis occurs as a result of other conditions.

Causes include

❖ Infections

❖ Autoimmune diseases

❖ Drugs

❖ Malignancies

PATHOPHYSIOLOGY OF VASCULITIS

Vasculitis is mainly an immune-related inflammatory disorder. In this condition, complex interactions between humoral and cellular immune systems cause damage to blood vessel

walls. The specific pathogenic pathway varies among the different types of vasculitis; however, injury to the endothelium and the resulting inflammatory responses are central to the disease's progression.

1. Role of Endothelial Injury

The vascular endothelium serves as a protective barrier and controls vascular tone, blood clotting, and immune responses. In vasculitis, endothelial cells get activated or damaged from immune attacks. This activation leads to increased expression of adhesion molecules, allowing inflammatory cells like neutrophils, macrophages, and lymphocytes to stick to the vessel wall and move into nearby tissue.

2. Immune Complex- Mediated Mechanism

In many types of small vessel vasculitis, circulating immune complexes made of antigens and antibodies get deposited in the vessel walls. These immune complexes activate the complement system, especially the classical pathway, which produces inflammatory mediators like C3a and C5a. These mediators attract neutrophils, which release enzymes and reactive oxygen species, resulting in vessel wall damage and increased permeability. This mechanism is commonly observed in leukocytoclastic vasculitis and Henoch-Schoenlein purpura.

3. ANCA- Associated Vasculitis

Anti- neutrophil cytoplasmic antibodies (ANCA)are crucial small vessel vasculitis type. ANCA bind to antigens in neutrophils, activating them. Activated neutrophils stick to the endothelium and release pro-inflammatory substance, causing necrotizing inflammation in blood vessels. In contrast to immune complex- mediated vasculitis, ANCA- associated vasculitis usually shows little immune complex deposition, pointing to a different pathogenic mechanism.

4. Cell-Mediated Immunity and Granuloma Formation

In large vessel vasculitis, such as giant cell arteritis and Takayasu arteritis, cell medicated immune response are dominant. Activated T-lymphocytes and macrophages invade the vessel wall and release cytokines like interferon-gamma and tumor necrosis factor-alpha. These cytokines promote chronic inflammation and the formation of granulomas, leading to the lumen, and reduced blood flow.

5.Role of Cytokines and Inflammatory Mediators

Cytokines and chemokines significantly boost vascular inflammation. Elevated levels of interleukins, TNF-α, and other inflammatory mediators lead to ongoing immune activation**,** endothelial dysfunction, and further vascular injury. These mediators also contribute to systemic symptoms, including fever, fatigue, and weight loss.

6.Vascular Remodelling and complication

Chronic inflammation results in structural changes in blood vessels, such as fibrosis, thrombosis, and aneurysms. Blockage of blood vessels leads to tissue ischemia and infarction, while dilated aneurysms increase the risk of rupture. These vascular changes cause specific complications in organs affected by vasculitis, including kidney failure, lung bleeding, and neurological problems.

CLINICAL FEATURES OF VASCULITIS

The clinical presentation of vasculitis varies widely. It depends on several factors, such as the size and type of blood vessels involved, the underlying cause, and the extent of organ involvement. Vasculitis can appear as a localized disease affecting one organ or as a systemic condition impacting multiple organs. This variability in symptoms often delays diagnosis and requires careful clinical observation.

1. Constitutional and systemic manifestations

A systemic inflammatory response is common in many forms of vasculitis. This response may appear before any organ-specific symptoms. The signs indicate ongoing immune activation and cytokine release.

- ❖ Fever of unknown origin
- ❖ Fatigue and generalized weakness
- ❖ Weight loss
- ❖ Malaise
- ❖ Anorexia

These nonspecific symptoms often occur in large and medium vessel vasculitis. They can mimic infections or cancers.

2. Cutaneous Manifestations

Skin involvement is a frequent clinical feature, especially in small vessel vasculitis. Skin signs often serve as an early warning for underlying systemic disease.

- Palpable purpura (the most characteristic feature)
- Petechiae and ecchymosis
- Urticarial lesions
- Nodules and ulcers
- Livedo reticularis

A histopathological exam of skin lesions usually shows leukocytoclastic vasculitis, which helps in diagnosis.

3. Musculoskeletal Involvement

Musculoskeletal symptoms are common and may greatly affect quality of life.

- Arthralgia
- Arthritis
- Myalgia

These symptoms are often symmetrical and can resemble inflammatory arthritis found in autoimmune disorders.

4. Renal Manifestations

Kidney involvement is a serious and potentially life-threatening feature, especially in ANCA-associated small vessel vasculitis.

- Haematuria
- Proteinuria
- Red blood cell casts
- Progressive glomerulonephritis
- Renal insufficiency

Early detection is essential since delayed treatment might cause irreversible kidney damage.

5. Pulmonary Manifestations

Lung involvement is often seen with small vessel vasculitis and can progress quickly.

- Dyspnoeas
- Cough

- Haemoptysis
- Pulmonary infiltrates
- Alveolar haemorrhage

Pulmonary-renal syndrome represents a severe form of systemic vasculitis that requires urgent treatment.

6. Neurological Manifestations

Nervous system involvement happens due to inflammation of the blood vessels supplying the nervous system.

- Peripheral neuropathy
- Mononeuritis multiplex
- Sensory loss
- Motor weakness
- Central nervous system involvement, such as stroke or seizures (rare but severe)

7. Gastrointestinal Manifestations

Vasculitis affecting mesenteric vessels causes gastrointestinal symptoms.

- Abdominal pain
- Nausea and vomiting
- Gastrointestinal bleeding
- Bowal ischemia and perforation (in severe cases)

These symptoms are more common in medium vessel vasculitis.

8. Cardiovascular and Ocular Manifestations

- Hypertension due to renal artery involvement
- Myocarditis and ischemia heart disease
- Coronary artery aneurysms (as seen in Kawasaki disease)

Visual disturbances and sudden vision loss (in cases of giant cell arteritis) Clinical Significance The wide range of clinical symptoms highlights the complexity of vasculitis. This complexity emphasizes the importance of early recognition and thorough systemic evaluation. Organ involvement influences disease severity, prognosis, and treatment approach.

MANAGEMENT AND TREATMENT OF VASCULITIS

The goal of managing vasculitis is to reduce vascular inflammation, prevent relapses, limit organ damage, and lower treatment-related side effects. Treatment plans are tailored based on the type of vasculitis, the size of the affected vessels, the severity of the disease, organ involvement, and individual patient factors. Early and aggressive treatment is vital, especially for life-threatening and organ-threatening forms of vasculitis.

1. General Principles of Management

- Early diagnosis and precise classification
- Assessment of disease severity and organ involvement
- Induction of remission followed by maintenance therapy
- Regular monitoring for disease activity and drug side effects
- Management of other health conditions and infections

2. Corticosteroid Therapy

Corticosteroids are a key part of treatment for most types of vasculitis due to their strong anti-inflammatory and immune-suppressing effects.

- Prednisone or prednisolone is commonly prescribed.
- High doses are used for severe or organ-threatening disease.
- Intravenous methylprednisolone pulses may be given in critical situations.
- Tapering off gradually is important to reduce side effects.

Long-term steroid use can lead to complications like osteoporosis, diabetes, hypertension, and infections. Therefore, steroid-sparing agents often are often needed.

3. Immunosuppressive Agents

Immunosuppressive medications help induce remission and maintain long-term disease control.

- Cyclophosphamide; Used for severe, life-threatening vasculitis such as ANCA-associated vasculitis. It effectively induces remission but needs careful monitoring due to toxicity.
- Methotrexate: Used for mild to moderate disease and as a maintenance therapy.
- Azathioprine: Commonly used for maintaining remission.
- Mycophenolate mofetil: An alternative maintenance agent with better tolerability in some patients.

4. Biological Therapies

Recent developments have led to targeted biological agents that improve outcomes and reduce dependence on steroids.

- Rituximab: A monoclonal antibody that targets CD20-positive B cells, widely used for ANCA- associated vasculitis.
- Tocilizumab: An interleukin-6 receptor blocker, effective for large vessel vasculitis like giant cell arteritis.

Biologic therapies provide targeted immune suppression with improved safety profiles for selected patients.

5. Plasma Exchange (Plasmapheresis)

Plasma exchange may be helpful in severe vasculitis with:

- Rapidly progressive glomerulonephritis
- Pulmonary haemorrhage
- High levels of circulating autoantibodies

It removes harmful antibodies and inflammatory mediators from the bloodstream.

6. Treatment of Secondary Vasculitis

Management focuses on treating the underlying cause:

- Antiviral therapy for infection-related vasculitis
- Stopping harmful medications
- Treating autoimmune or cancer conditions

7. Supportive and Adjunctive Therapy

- Antihypertensive therapy for kidney involvement
- Antibiotic prophylaxis during immunosuppressive treatment
- Calcium and vitamin D supplements
- Vaccination and infection prevention
- Pain management and physical therapy

8. Monitoring and Follow-up Regular monitoring is crucial to

- Evaluate disease activity and remission
- Detect relapses early
- Monitor for drug toxicity

- Assess organ function

Laboratory tests, imaging studies, and clinical assessments are important for long-term follow-up.

9. Prognosis and Outcome

With early diagnosis and proper treatment, the prognosis for vasculitis has improved significantly. However, delays in treatment, severe organ involvement, and recurrent relapses can lead to poor outcomes. Long-term follow-up is important to prevent complications and enhance quality of life.

RECENT ADVANCES IN THE MANAGEMENT OF VASCULITIS

Over the past few decades, we have made significant progress in understanding the immune mechanisms involved in vasculitis. These developments have led to new diagnostic tools and targeted treatment strategies that have greatly improved patient outcomes. Traditional treatments mainly used high-dose corticosteroids and cytotoxic immunosuppressive drugs. However, recent advances now focus on targeted therapy, better disease monitoring, and personalized treatment plans to reduce toxicity and improve long- term disease control.

1. Targeted Biological Therapies

One of the key advancements in managing vasculitis is the introduction of biologic agents that target specific parts of the immune system. These therapies aim to block crucial inflammatory pathways linked to blood vessel damage.

Monoclonal antibodies like rituximab have shown great success in treating ANCA-associated vasculitis. Rituximab selectively reduces B lymphocytes that produce harmful autoantibodies. Clinical studies indicate that rituximab is an effective as traditional cyclophosphamide therapy for inducing remission while also lowering long-term toxicity.

Another notable biologic therapy is tocilizumab, an interleukin-6 receptor inhibitor that has shown success in large vessel vasculitis, particularly giant cell arteritis. By blocking vascular inflammation and significantly cuts down the need for extended corticosteroid therapy. Other new biologic therapies targeting tumor necrosis factor- alpha (TNF-α) and other cytokines are also being studied for their role in controlling disease activity and preventing relapse.

2. Steroid- Sparing Treatment Strategies

Long-term corticosteroid therapy has traditionally been the foundation of vasculitis treatment. However, ongoing steroid use is linked to may side effects like osteoporosis, diabetes, hypertension, and higher infection risk. Recent treatment strategies aim to reduce steroid exposure by using immunosuppressive agents and biologic therapies.

Low- dose steroid regimens combined with immunomodulatory drugs like methotrexate, azathioprine, or mycophenolate mofetil have shown promising and reducing steroid- related complications.

3.Advances in Diagnostic and Imaging Techniques

New diagnostic technologies have improved early detection and monitoring of vasculitis. Imaging methods such as positron emission tomography (PET), computed tomography angiography (CTA), and magnetic resonance angiography (MRA)allow for detailed visualizations of vascular inflammation and structural issues. These techniques are particularly helpful in diagnosing large vessel walls and inflammatory changes, especially in conditions like giant cell arteritis.

4.Biomarkers for Disease Monitoring

Recent studies have focused on finding reliable biomarkers that can help in early diagnosis, disease monitoring, and predicting relapse. Anti-neutrophil cytoplasmic antibodies (ANCA)remain key markers for small vessel vasculitis. Monitoring ANCA levels can assist in assessing disease activity and guiding treatment decisions. Other inflammatory markers like C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and cytokine profiles are also used to evaluate disease progression and treatment response.

5.Personalized Medicine Approaches

Modern management of vasculitis is increasing leaning toward personalized medicine. This approach considers individual patient factors such as disease type, severity, organ involvement, genetic factor, and previous treatment responses. Tailoring treatment plans to these factors helps optimize outcomes while minimizing side effect

Improved supportive and preventive care advances in supportive care have also led to better patient outcomes. Preventive strategies include vaccination against infection, monitoring for drug side effects, and managing cardiovascular risk factors. Early rehabilitation and

multidisciplinary care from rheumatologists, neurologists further enhance long- term disease management.

6.Ongoing Research and Emerging Therapies

Current research continues to explore new therapeutic targets and immunomodulatory drugs that can offer more effective and safer treatment options. New agents focused on specific immune pathways, components of the complement system, and inflammatory mediators are being investigated. These therapies aim to provide better disease control with fewer side effects, improving the quality of life for patients.

CONCLUSION

Vasculitis is a varied and complex group of inflammatory disorders that cause inflammation and damage to blood vessel of all sizes, including large, medium, and small ones, and digestive system, and digestive system. Due to its diverse clinical presentation, vasculitis often presents significant diagnostic challenges and can lead to serious complication if not identified and treated early. Recent improvements in understanding the immune and pathological mechanisms behind vasculitis have greatly helped with the classification, diagnosis, and treatment of the disease. Identifying immune pathways, including the role of autoantibodies like ANCA and inflammatory cytokines, has improved knowledge of disease progression and organ involvement. These findings have led to the development of more targeted and effective treatment strategies. Early diagnosis is crucial for preventing irreversible organ damage and improving patient outcomes. Clinical evaluations, supported by lab tests, imaging studies, and tissue examinations, are essential for accurate diagnosis and disease monitoring. A team approach with specialities from various fields is often needed to ensure effective management of patients with systemic vasculitis. Treatment of vasculitis has changed significantly over the years. While corticosteroids and traditional immunosuppressive drugs remain the main treatments, the introduction of targeted biological therapies has transformed disease management. These therapies not only increase remission rates but also lower long- term complications linked to prolonged steroid use. Additionally, advancements in diagnostic imaging and biomarker research have improved the ability to track disease activity and evaluate treatment response. Despite these advancements, vasculitis still carries significant risks of illness and potential death, especially in cases with severe organ involvement. Therefore, ongoing research to identify new biomarkers, understand genetic factors, and develop safer targeted therapies is crucial. Future developments in

personalized medicine are expected to further improve treatment strategies and long-term outcomes. Ln summery, vasculitis is a challenging but increasingly manageable condition due to progress in medical research and treatment innovations. Ongoing efforts in early detection, improved diagnostic methods, and targeted treatment approaches are vital for enhancing patient care and quality of life.

REFERENCES

1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum., 2013; 65(1): 1–11.
2. Kitching AR, Anders HJ, Basu N, Brouwer E, Gordon J, Jayne DR, et al. ANCA associated vasculitis. Nat Rev Dis Primers. 2020;6(1):71. Pagnoux C. Updates in vasculitis. Jt Bone Spine, 2016; 83(6): 615–9.
3. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of vasculitis. Ann Rheum Dis., 2007; 66(2): 222–7.
4. Robson JC, Grayson PC, Ponte C, Suppiah R, Judge A, Khalid S, et al. 2022 American College of Rheumatology/European Alliance classification criteria for vasculitis. Ann Rheum Dis., 2022; 81(3): 315–20.
5. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet., 2008; 372(9634): 234–45.
6. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. N Engl. J Med., 2014; 371(1): 50–7.
7. Stone JH. Vasculitis: A collection of pearls and myths. Rheum. Dis. Clin. North. Am., 2007; 33(4): 733–44.
8. Mahr A, Katsahian S, Varet H, Guillevin L, Hagen EC, Hoglund P, et al. Revisiting classification of systemic vasculitides. Ann Rheum. Dis., 2013; 72(9): 1407–12.
9. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: An analysis of 158 patients. Ann Intern. Med., 1992; 116(6): 488–98.
10. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl. J Med., 1997; 337(21): 1512–23. Pendergraft WF, Nachman PH. Recent advances in the pathogenesis of ANCA associated vasculitis. Clin. J Am Soc. Nephrol., 2014; 9(3): 539–48.

11. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Toumelin PL. The Five-Factor Score revisited. Medicine (Baltimore)., 2011; 90(1): 19–27.
12. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for management of vasculitis. Ann Rheum. Dis., 2007; 66(5): 571–6.
13. Yates M, Watts R, Bajema I, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for ANCA-associated vasculitis. Ann Rheum. Dis., 2016; 75(9): 1583 94.
14. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide. N Engl. J Med., 2010; 363(3): 221–32.
15. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. Randomized trial of cyclophosphamide. N Engl. J Med., 2003; 349(1): 36–44.
16. Furuta S, Jayne DR. Emerging therapies in ANCA-associated vasculitis. Nat. Rev. Rheumatol., 2018; 14(12): 713–24.
17. McGeoch L, Twilt M, Famorca L, Bakowsky V, Barra L, Benseler SM, et al. Can. Vasc. recommendations. J Rheumatol., 2015; 42(1): 97–103.
18. Cid MC, Font C, Oristrell J, de la Sierra A, Coll-Vinent B, López-Soto A, et al. Clinical spectrum of vasculitis. Medicine (Baltimore)., 1998; 77(5): 292–308.
19. Lamprecht P, Kerstein A, Klapa S, Schinke S, Karsten CM, Yu X, et al. Pathogenetic concepts of vasculitis. Autoimmun Rev., 2018; 17(3): 241–9.
20. Sunderkötter C, Zelger B, Chen KR, Requena L, Piette W, Carlson JA, et al. Nomenclature of cutaneous vasculitis. J Am Acad Dermatol., 2018; 78(5): 777–86. Kallenberg CG. Pathogenesis and treatment of ANCA-associated vasculitis. Clin Exp Rheumatol., 2015; 33(2 Suppl 89): S11–4.
21. Ntatsaki E, Carruthers D, Chakravarty K, D'Cruz D, Harper L, Jayne D, et al. BSR guidelines for management of vasculitis. Rheumatology (Oxford)., 2014; 53(12): 2306–9.